Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2019-07-15
2021-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TO ASSESS THE EFFECTIVENESS OF THE INTERVENTION OF THE LOW-SODIUM DIET IN PATIENTS WITH HTA
NCT04677322
Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
NCT00387621
Blood Pressure and Diurnal Variation in Sodium, Potassium, and Water Excretion
NCT00005204
Non-invasive Haemodynamic Assessment in Hypertension
NCT01996085
Fludrocortisone's Test in Salt Sensitivity
NCT01453959
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
3.3.3 ABLOOD PRESSURE MONITORING - 24 HOURS Ambulatorial blood pressure monitoring 24-hour will be performed using a Mobil-O-Graph® compact digital device (version 12, ambulatory pressure monitor, 2000, UK). Individuals will be instructed to maintain their normal activities of daily living. The device will be pre-programmed to measure blood pressure within 24 hours at 30-minute intervals every hour during the waking period and at 1-hour intervals during sleep. This device will evaluate the following parameters: systolic and peripheral diastolic blood pressure, mean arterial pressure, pulse pressure, systolic central aortic pressure, central diastolic aortic pressure (cDBP), central pulse pressure (cPP), augmentation index corrected for 75 bpm (AI75%) and pulse wave velocity (PWV).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Controlled Hypertensive Patients (CHP)
Hypertensive patients that have blood pressure less than 140 x 90 mmHg. This parameter must be evaluated by ambulatory blood pressure monitoring
No interventions assigned to this group
Resistant Hypertensive Patients (RHP)
Hypertensive patients that have blood pressure more than 140 x 90 mmHg and they use three antihypertensive medicines; or hypertensive patients that have blood pressure less than 140 x 90 mmHg, but they use four or more antihypertensive medicines. This parameter must be evaluated by ambulatory blood pressure monitoring.
Evaluate if the individuals are resistant hypertensive patients
Evaluation of the individuals has the objective determine if they are resistant hypertensive patients. This is important because the resistant people have worse prognosis than the controlled people and need more attention from the health professionals. Analysis must be done using the ambulatory blood pressure monitoring.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Evaluate if the individuals are resistant hypertensive patients
Evaluation of the individuals has the objective determine if they are resistant hypertensive patients. This is important because the resistant people have worse prognosis than the controlled people and need more attention from the health professionals. Analysis must be done using the ambulatory blood pressure monitoring.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* hypertensive patient for more than four weeks;
* controlled hypertension;
* resistant hypertension;
* regular patient in the local where the study will be done.
Exclusion Criteria
* been in the hospital in last 60 days;
* used vasoactive drugs in last 30 days;
* heart failure in III or IV functional class (NYHA);
* pregnant/breastfeeding;
* serious liver disease;
* HIV positive;
* psychiatric diseases that make it difficult to participate;
* stroke or acute myocardial infarction in last 30 days;
* cancer with prognosis less than one year.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sao Jose do Rio Preto Medical School
OTHER
Hospital de Base
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
JOSE FERNANDO VILELA-MARTIN
Principal Investigator and Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
José F Vilela-Martin, MD PhD FAHA
Role: PRINCIPAL_INVESTIGATOR
State Medical School at São José do Rio Preto (FAMERP), São Paulo, Brazil
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fundação Faculdade Regional de Medicina (FUNFARME)
São José do Rio Preto, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHASSI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.